EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Early versus late response to PD-1-based immunotherapy in metastatic melanoma

Georg C Lodde, Fang Zhao, Rudolf Herbst, Patrick Terheyden, Jochen Utikal, Claudia Pföhler, Jens Ulrich, Alexander Kreuter, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Edgar Dippel und 23 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114295 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Georg C Lodde und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany. Electronic address: georg.lodde@uk-essen.de. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Melanoma, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universität Duisburg-Essen Universitatsbibliothek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune checkpoint inhibition (ICI) currently is the most effective treatment to induce durable responses in metastatic melanoma. The aims of this study are the characterization of patients with early, late and non-response to ICI and analysis of survival outcomes in a real-world patient cohort. METHODS: Patients who received PD-1-based immunotherapy for non-resectable stage-IV melanoma in any therapy line were selected from the prospective multicenter real-world DeCOG study ADOREG-TRIM (NCT05750511). Patients showing complete (CR) or partial (PR) response already during the first 3 months of treatment (Early Responders, EarlyR) were compared to patients showing CR/PR at a later time (Late Responders, LateR), a stable disease (SD) and to patients showing progressive disease (Non-Responders, NonR). RESULTS: Of 522 patients, 8.2 % were EarlyR (n = 43), 19.0 % were LateR (n = 99), 37.0 % had a SD (n = 193) and 35.8 % were NonR (n = 187). EarlyR, LateR and SD patients had comparable baseline characteristics. Multivariate logbinomial regression analyses adjusted for age and sex revealed positive tumor PD-L1 (RR=1.99, 95 %-CI=1.14-3.46, p = 0.015), and normal serum CRP (RR=1.59, 95 %-CI=0.93-2.70, p = 0.036) as independently associated with the achievement of an early response compared to NonR. The median progression-free and overall survival was 46.0 months (95 % CI 19.1; NR) and 47.8 months (95 %-CI 36.9; NR) for EarlyR, NR (95 %-CI NR; NR) for LateR, 8.1 months (7.0; 10.4) and 35.4 months (29.2; NR) for SD, and 2.0 months (95 %-CI 1.9; 2.1) and 6.1 months (95 %-CI 4.6; 8.8) for NonR patients. CONCLUSION: Less than 10 % of metastatic melanoma patients achieved an early response during the first 3 months of PD-1-based immunotherapy. Early responders were not superior to late responders in terms of response durability and survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsMelanomaProgrammed Cell Death 1 ReceptorAdultAgedFemaleHumansMaleMiddle AgedImmunotherapyProspective StudiesSkin NeoplasmsTime Factors

Stichwörter der Autor:innen

Best overall responseCTLA-4Immune checkpoint inhibitionImmunotherapyMelanomaPD-1PD-L1SurvivalTherapy outcome

Substanzen

Immune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany. Electronic address: georg.lodde@uk-essen.de.
  • Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany. Electronic address: fang.zhao@uk-essen.de.
  • Department of Dermatology, Helios Klinikum Erfurt, Erfurt, Germany. Electronic address: rudolf.herbst@helios-gesundheit.de.
  • Department of Dermatology, UKSH Campus Lübeck, Lübeck, Germany. Electronic address: patrick.terheyden@uksh.de.
  • Department of Dermatology, Venerology, and Allergology, University Medical Center, Ruprecht-Karls University of Heidelberg, 68167 Mannheim, Germany. Electronic address: jochen.utikal@umm.de.
  • Department of Dermatology, Saarland University Medical School, Homburg, Saar, Germany. Electronic address: claudia.pfoehler@uks.eu.

Förderung

  • Universität Duisburg-Essen Universitatsbibliothek

Zitieren

APA

Lodde, G. C., Zhao, F., Herbst, R., Terheyden, P., Utikal, J., Pföhler, C., Ulrich, J., Kreuter, A., Mohr, P., Gutzmer, R., Meier, F., Dippel, E., Weichenthal, M., Jansen, P., Kowall, B., Galetzka, W., Hörst, F., Kleesiek, J., Hellwig, B., …, & Ugurel, S. (2024). Early versus late response to PD-1-based immunotherapy in metastatic melanoma. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114295

Vancouver

Lodde GC, Zhao F, Herbst R, Terheyden P, Utikal J, Pföhler C, et al. Early versus late response to PD-1-based immunotherapy in metastatic melanoma. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114295

BibTeX
@article{Lodde2024,
  author = {Lodde, Georg C and Zhao, Fang and Herbst, Rudolf and Terheyden, Patrick and Utikal, Jochen and Pföhler, Claudia and Ulrich, Jens and Kreuter, Alexander and Mohr, Peter and Gutzmer, Ralf and Meier, Friedegund and Dippel, Edgar and Weichenthal, Michael and Jansen, Philipp and Kowall, Bernd and Galetzka, Wolfgang and Hörst, Fabian and Kleesiek, Jens and Hellwig, Birte and Rahnenführer, Jörg and Rajcsanyi, Luisa and Peters, Triinu and Hinney, Anke and Placke, Jan-Malte and Sucker, Antje and Paschen, Annette and Becker, Jürgen C and Livingstone, Elisabeth and Zimmer, Lisa and Tasdogan, Alpaslan and Roesch, Alexander and Hadaschik, Eva and Schadendorf, Dirk and Griewank, Klaus and Ugurel, Selma},
  title = {Early versus late response to PD-1-based immunotherapy in metastatic melanoma},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114295}
}
Kostenlos starten →